docetaxel anhydrous has been researched along with Ache in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.35) | 18.2507 |
| 2000's | 20 (43.48) | 29.6817 |
| 2010's | 16 (34.78) | 24.3611 |
| 2020's | 8 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, M; Hojo, M; Iikura, M; Ishida, A; Ishii, S; Izumi, S; Naka, G; Sugiyama, H; Ushio, A | 1 |
| Alcaraz, A; Alekseev, B; Armstrong, AJ; Azad, A; Ganguli, A; Gomez-Veiga, F; Haas, GP; Holzbeierlein, J; Iguchi, T; Ivanescu, C; Petrylak, D; Ramaswamy, K; Rosbrook, B; Shore, ND; Stenzl, A; Szmulewitz, RZ; Villers, A | 1 |
| Alekseev, B; Burgents, J; Chiuri, VE; Clarke, NW; Degboe, A; Fléchon, A; Gresty, C; Jassem, J; Jones, R; Kang, J; Kocak, I; Redfern, C; Saad, F; Sala, N; Thiery-Vuillemin, A; Wiechno, P | 1 |
| Alibhai, SMH; Breunis, H; Emmenegger, U; Gregg, R; Hansen, AR; Kim, VS; Timilshina, N; Tomlinson, G; Yang, H | 1 |
| Chen, CH; Chen, IA; Chen, YH; Chen, YT; Cheng, YT; Chiang, PC; Chiang, PH; Kang, CH; Liu, YY; Luo, HL; Su, YL; Wang, HJ | 1 |
| Halabi, S; McSweeney, S; Morgans, AK; Oyenuga, A; Oyenuga, M; Prizment, A; Ryan, CJ | 1 |
| Matta, C; Mensah-Nyagan, AG; Meyer, L; Taleb, O | 1 |
| Bury, D; de Bono, J; Eisenberger, M; Fizazi, K; Oudard, S; Ozatilgan, A; Poole, EM; Sartor, O; Thiery-Vuillemin, A | 1 |
| Albiges, L; Bernard, B; Francini, E; Gray, KP; Harshman, LC; Kantoff, PW; Shaw, GK; Sweeney, CJ; Taplin, ME; Valença, L; Xie, W | 1 |
| Arving, C; Fjällskog, ML; Hellerstedt-Börjesson, S; Nordin, K; Peterson, M; Rissanen, R | 1 |
| Cuevas Sanz, JM; García García-Porrero, Á; González-Del-Alba, A; Méndez-Vidal, MJ; Muñoz Del Toro, JR; Pinto, A; Puente, J; Rodríguez, Á; Sala-Gonzalez, N; Useros Rodríguez, E; Vázquez, S | 1 |
| Cheung, FY; Leung, KC; Ngan, RK | 1 |
| Bahl, A; de Bono, JS; Devin, J; Gravis, G; Hansen, S; Kocak, I; Oudard, S; Ozgüroglu, M; Sartor, AO; Shen, L; Tombal, B | 1 |
| Autio, KA; Basch, EM; Beer, TM; Bennett, AV; Carducci, MA; Fruscione, M; George, DJ; Jia, X; Kane, RC; Logothetis, CJ; Morris, MJ; Rogak, L; Scher, HI; Sit, L | 1 |
| Armstrong, AJ; de Bono, J; Halabi, S; Kaplan, EB; Lin, CY; Oudard, S; Petrylak, D; Sartor, O; Shen, L; Small, EJ; Sternberg, CN | 1 |
| Dass, RN; Diels, J; Ford, D; Hamberg, P; Price, PW; Spencer, M | 1 |
| Dreicer, R | 1 |
| Finnerup, NB; Jensen, AB; Jensen, AR; Jensen, TS; Ventzel, L | 1 |
| Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E | 1 |
| Donaldson, GW; Moinpour, CM; Nakamura, Y | 1 |
| Andrieu, JM; Banu, A; Banu, E; Kacso, G; Levy, E; Medioni, J; Oudard, S; Scotte, F; Wasserman, J | 1 |
| Beuzeboc, P; Bouzy, J; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Haddad, V; Laplanche, A; Loriot, Y; Lumbroso, J; Massard, C; Theodore, C; Tournay, E | 1 |
| Johnson, MM; Jones, D; Logothetis, CJ; Mathew, P; Tu, SM; Wong, FC | 1 |
| Bentzen, L; Buch-Hansen, TZ; Hansen, S; Hoeyer, M; Jensen, NV; Saxe, C; Sengeloev, L | 1 |
| Burris, HA; de Bono, JS; Hubner, A; Miller, K; Morris, T; Nathan, F; Payne, H; Stephenson, J; Taboada, M; Trump, DL | 1 |
| Federico, K; Lloyd, GK; Mainwaring, P; Millward, M; Mita, A; Mita, M; Nawrocki, S; Reddinger, N; Spear, MA | 1 |
| Caffo, O; Comploj, E; Fariello, A; Galligioni, E; Sacco, C; Sava, T; Segati, R; Veccia, A; Zustovich, F | 1 |
| Deuss, B; Dickgreber, N; Nagel, S; Pabst, S; Roscher, K; Salm, T; Schuette, W; Schumann, C; von Weikersthal, LF | 1 |
| Coenen, JL; Creemers, GJ; Dalesio, O; de Jong, PC; de Wit, R; Fosså, SD; Gerritsen, W; Loosveld, OJ; Meulenbeld, HJ; Polee, M; Ten Tije, AJ; van Werkhoven, ED | 1 |
| Glaspy, J; Green, MD; Hackett, J; Holmes, FA; Kubista, E; Neumann, T | 1 |
| Dancey, J; Gralla, RJ; Kim, YS; Shepherd, FA | 1 |
| Beer, TM; Eilers, KM; Garzotto, M; Hsieh, YC; Mori, M | 1 |
| Johannsen, M; Loening, SA; Schnorr, D; Wilke, K | 1 |
| Ahmad, K | 1 |
| Antoniou, N; Bamias, A; Bozas, G; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostakopoulos, A; Papadimitriou, C; Skarlos, D | 1 |
| Hamel, K; Hamolsky, D; Melisko, M; Topp, KS; Wampler, MA | 1 |
| Ankerst, DP; Berry, DL; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, S; Lara, PN; Moinpour, CM; Petrylak, DP; Taplin, ME; Vinson, LV | 1 |
| Belani, CP; Fidias, P; Fossella, F; Gorbounova, V; Kaukel, E; Mattson, KV; Millward, M; Pereira, JR; Pluzanska, A; Ramlau, R; Szczesna, A; von Pawel, J | 1 |
| Lester, JF; Macbeth, FR | 1 |
| Armstrong, AJ; Carducci, MA; de Wit, R; Eisenberger, M; Garrett-Mayer, E; Ou Yang, YC; Tannock, I | 1 |
| Berthold, DR; de Wit, R; Eisenberger, M; Pond, GR; Roessner, M; Tannock, AI | 1 |
| Bagiella, E; Balog, J; Benson, M; Fine, R; Heitjan, D; Judge, T; Macarthur, RB; O'Connor, J; Olsson, CA; Petrylak, DP; Pfaff, C; Sawczuk, I; Shelton, G; Zuech, N | 1 |
| Bernard, S; van Deventer, H | 1 |
| Godley, PA; Herndon, JE; Kornblith, AB; Savarese, D; Vogelzang, NJ; Zuckerman, E | 1 |
| Beer, TM; Henner, WD; Lowe, BA; Pierce, WC | 1 |
| Beer, TM; Bubalo, JS | 1 |
4 review(s) available for docetaxel anhydrous and Ache
| Article | Year |
|---|---|
Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan.
Topics: Alkaline Phosphatase; Docetaxel; Humans; Male; Pain; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Taiwan; Treatment Outcome | 2023 |
[Taxanes in the chemotherapy of hormone-refractory prostate carcinoma].
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Pain; Palliative Care; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2004 |
Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer.
Topics: Activities of Daily Living; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Diabetes Mellitus, Type 1; Disease Progression; Docetaxel; Exercise Therapy; Female; Hand Strength; Humans; Middle Aged; Nurse's Role; Oncology Nursing; Pain; Pain Management; Pain Measurement; Patient Care Team; Peripheral Nervous System Diseases; Quality of Life; Severity of Illness Index; Taxoids | 2005 |
Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer.
Topics: Aged; Androgens; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Male; Paclitaxel; Pain; Prostatic Neoplasms; Taxoids | 2002 |
25 trial(s) available for docetaxel anhydrous and Ache
| Article | Year |
|---|---|
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Topics: Androgen Antagonists; Benzamides; Docetaxel; Hormones; Humans; Male; Nitriles; Pain; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2022 |
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Humans; Male; Pain; Patient Reported Outcome Measures; Phthalazines; Piperazines; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone | 2022 |
Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Pain; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Treatment Outcome | 2021 |
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Pain; Pain Measurement; Palliative Care; Peripheral Nervous System Diseases; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Survival; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Hemoglobins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Models, Statistical; Multivariate Analysis; Nomograms; Organoplatinum Compounds; Pain; Predictive Value of Tests; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2013 |
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Pain; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Models, Statistical; Neoplasms, Hormone-Dependent; Pain; Pain Measurement; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2009 |
What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Pain; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Severity of Illness Index; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
Topics: Aged; Analgesics, Non-Narcotic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Pain; Pain Measurement; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Taxoids | 2009 |
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Constipation; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Feasibility Studies; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Orchiectomy; Organometallic Compounds; Organophosphorus Compounds; Pain; Platelet Count; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Taxoids | 2009 |
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Endpoint Determination; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Pain; Palliative Care; Prednisone; Prostatic Neoplasms; Survival Analysis; Taxoids | 2010 |
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Orchiectomy; Pain; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome | 2011 |
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Diketopiperazines; Docetaxel; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Pain; Taxoids; Vomiting | 2012 |
Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chronic Disease; Docetaxel; Estramustine; Humans; Male; Middle Aged; Orchiectomy; Pain; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids | 2011 |
Randomized phase III trial of docetaxel plus carboplatin with or without levofloxacin prophylaxis in elderly patients with advanced non-small cell lung cancer: the APRONTA trial.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Dyspnea; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukopenia; Levofloxacin; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ofloxacin; Pain; Taxoids | 2011 |
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Castration; Disease Progression; Docetaxel; Etidronic Acid; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Netherlands; Norway; Pain; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risedronic Acid; Risk Assessment; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2012 |
Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Fatigue; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pain; Quality of Life; Salvage Therapy; Survival Analysis; Taxoids | 2004 |
Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents, Phytogenic; Calcitriol; Calcium Channel Agonists; Docetaxel; Health Status; Humans; Male; Middle Aged; Pain; Pain Measurement; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome | 2004 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Pain; Pain Measurement; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids | 2006 |
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pain; Patient Compliance; Platinum; Prospective Studies; Psychomotor Performance; Quality of Life; Sickness Impact Profile; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Comorbidity; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Pain; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2007 |
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Mitoxantrone; Pain; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids | 2008 |
Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Estramustine; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Middle Aged; Paclitaxel; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Docetaxel; Drug Resistance, Neoplasm; Emotions; Estramustine; Feasibility Studies; Female; Health Status; Humans; Hydrocortisone; Infusions, Intravenous; Male; Mental Health; Middle Aged; Paclitaxel; Pain; Prostatic Neoplasms; Quality of Life; Sexual Behavior; Spouses; Taxoids | 2001 |
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents, Phytogenic; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2001 |
17 other study(ies) available for docetaxel anhydrous and Ache
| Article | Year |
|---|---|
A rare case of docetaxel-induced myositis in a patient with a lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Docetaxel; Fatigue; Humans; Lung Neoplasms; Male; Myositis; Pain | 2022 |
The role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer.
Topics: Activities of Daily Living; Aged; Docetaxel; Fatigue; Frailty; Humans; Male; Pain; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2023 |
Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score.
Topics: Aged; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Pain; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Treatment Outcome | 2023 |
Behavioral, Electrophysiological, and Histological Characterization of a New Rat Model for Neoadjuvant Chemotherapy-Induced Neuropathic Pain: Therapeutic Potential of Duloxetine and Allopregnanolone Concomitant Treatment.
Topics: Analgesics; Animals; Antineoplastic Agents; Disease Models, Animal; Docetaxel; Duloxetine Hydrochloride; Epirubicin; Female; Neoadjuvant Therapy; Neuralgia; Pain; Pain Measurement; Peripheral Nervous System Diseases; Pregnanolone; Sciatic Nerve | 2020 |
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Registries; Retrospective Studies; Survival Rate; Time Factors | 2018 |
Colored body images reveal the perceived intensity and distribution of pain in women with breast cancer treated with adjuvant taxanes: a prospective multi-method study of pain experiences.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Pain; Pain Measurement; Prospective Studies; Taxoids | 2018 |
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
Topics: Abiraterone Acetate; Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Docetaxel; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Multivariate Analysis; Pain; Prednisone; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Spain; Taxoids; Treatment Outcome | 2019 |
Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Disease-Free Survival; Docetaxel; Hong Kong; Humans; Male; Middle Aged; Pain; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Tertiary Care Centers; Treatment Outcome | 2013 |
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.
Topics: Adult; Aged; Analgesics; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Male; Middle Aged; Pain; Patient Outcome Assessment; Prevalence; Prostatic Neoplasms; Self Report; Taxoids | 2013 |
Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients.
Topics: Adrenal Cortex Hormones; Aged; Algorithms; Antineoplastic Agents; Bone Neoplasms; Cross-Sectional Studies; Diphosphonates; Docetaxel; Europe; Health Status; Humans; Male; Models, Theoretical; Pain; Pain Management; Palliative Care; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Surveys and Questionnaires; Taxoids | 2015 |
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Brachytherapy; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Pain; Pain Measurement; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radium; Taxoids | 2015 |
Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel.
Topics: Adult; Aged; Antineoplastic Agents; Docetaxel; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pain; Peripheral Nervous System Diseases; Prospective Studies; Quality of Life; Surveys and Questionnaires; Taxoids | 2016 |
Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Docetaxel; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Middle Aged; Multicenter Studies as Topic; Narcotics; Neoplasm Metastasis; Paclitaxel; Pain; Pain Measurement; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Taxoids | 2003 |
New progress in treatment of hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Pain; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alopecia; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Orchiectomy; Pain; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid | 2005 |
Quality of life assessment in the TAX 326 study.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pain; Patient Compliance; Platinum; Psychomotor Performance; Quality of Life; Sickness Impact Profile; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Use of gabapentin to treat taxane-induced myalgias.
Topics: Acetates; Amines; Analgesics; Antineoplastic Agents, Phytogenic; Cyclohexanecarboxylic Acids; Docetaxel; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Middle Aged; Muscular Diseases; Paclitaxel; Pain; Taxoids | 1999 |